2024 Medical Fee Revision Implemented, Impact on Medical Corporations Investigated – M&A Capital Partners

Impact of the FY2024 Medical Fee Revision on Medical Corporation Management and Implications for M&A

The FY2024 medical fee revision directly impacts the revenue structure of medical institutions, necessitating a review of mid-to-long-term management strategies. In particular, trends such as stricter facility standards and expanded utilization of regional medical collaboration promotion corporations significantly influence the management decisions of individual medical corporations.

Amidst the accelerating pace of such regulatory changes, the importance of mid-to-long-term management and succession strategies, considering the revision cycle, is increasing in the context of medical M&A and business succession. Mergers and consolidations pursuing economies of scale can be effective options for medical corporations finding it difficult to continue operating independently, offering benefits in maintaining facility standards, distributing the burden of high-value capital investments, and securing specialized personnel. Furthermore, utilizing tax schemes, including transitions to specific medical corporations or social medical corporations, emerges as a consideration for business succession.

Medical institution executives and those facing succession issues should view this medical fee revision not merely as an opportunity for revenue fluctuation, but as a catalyst for concretely considering business succession and M&A strategies to enhance their institution's sustainability. Adapting to regulatory changes and joining a group that can leverage economies of scale will be key to broadening future options.